Recent news on Cladribine

Increased Risk of Second Malignancies in Hairy Cell Leukemia  -  Feb 15, 2007
Cancer Consultants (press release),Patients are usually treated initially with Leustatin® (2-CdA, cladribine) which results in reported relapse-free survivals of 70-80% at 4-5 years.

Merck Serono Completes Patient Enrollment in CLARITY Phase III ...  -  Jan 16, 2007
Drug Newswire (press release),..."The completion of patient enrollment into the CLARITY pivotal trial is a major milestone in the development program of oral cladribine," said Franck

Sección internacional  -  Jan 15, 2007
Bolsamania.com,...(PRN) - Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine ... [+]

Biotech Stocks Day-in-Review: BioCryst Begins Pivotal Trial of ...  -  Jan 17, 2007
Seeking Alpha,Merck Serono [SRA] has completed enrollment in a Phase III trial of an oral formulation of cladribine for relapsing forms of multiple sclerosis.

Sección internacional  -  Jan 16, 2007
Bolsamania.com,...(PRN) - Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine ... [+]

Sección internacional  -  Jan 16, 2007
Bolsamania.com,...(PRN) - Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine ... [+]

(PRN) - Following Is a Test Release ... [+]  -  Jan 15, 2007
Bolsamania.com,...(PRN) - Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine ... [+]

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)Oral cladribine is currently being investigated in a phase 3, multicenter international trial for MS. Although the results of this trial are pending,

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  Dec 12, 2006
Drug Newswire (press release),Additional therapeutic options are currently under development at Serono, including oral cladribine, currently in Phase III studies and potentially the

2006 - A Very Good Year in MS Research  -  Dec 7, 2006
PR Newswire (press release),...a large phase III trial is now underway; -- oral cladribine (an immune-modulating drug by Serono), now being tested in an international Phase 3 clinical

Scientists improve cancer drug synthesis  Nov 2, 2006
02/11/2006 - Researchers have developed a more efficient and cost-saving method to make cladribine, a drug used for the treatment of certain types of leukaemia ... -In-PharmaTechnologist.com, US FDA gives fast track status to Serono's oral cladribine for ...  Oct 12, 2006
Serono (SEO) announced that oral cladribine has been designated a fast track product by the US Food and Drug Administration (FDA). ... -Therapeutics Daily (subscription) (press release), BYU scientists offer a new way to manufacture cancer drug  Oct 30, 2006
...of cancer. The new manufacturing method is considered a more efficient way to synthesize the drug known as cladribine. The findings ... -Salt Lake Tribune, Serono Q3 Adj. Profit Rises 15.5% On Strong Sales Of Rebif And ...  Oct 19, 2006
In September 2006, oral drug, cladribine was designated a Fast Track product for patients with relapsing forms of multiple sclerosis by the US Food and Drug ... -Trading Markets, Serono Delivers Strong Adjusted* Net Income of $183.5m in Third ...  Oct 18, 2006
...in several R&D programs: - In-licensing of safinamide in early Phase 3 in Parkinson's Disease - Fast Track designation for oral cladribine in relapsing forms ... -PR Newswire (press release), Serono posts better-than-forecast Q3 results, driven by MS drug ...  Oct 19, 2006
Cladribine treatment Novantrone sales in the third quarter were 2.8 mln usd, down 84.6 pct hit by the introduction of generics in the US in April 2006. ... -Forbes, Pharma Earnings On Tap-Upcoming Week In Earnings  Oct 17, 2006
In late September, Serono said it received a Fast Track product designation from the FDA for its purine nucleoside analogue, cladribine. ... -Trading Markets, Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  12 Dec 2006
PharmaLive.com (press release),Additional therapeutic options are currently under development at Serono, including oral cladribine, currently in Phase III studies and potentially the

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)Oral cladribine is currently being investigated in a phase 3, multicenter international trial for MS. Although the results of this trial are pending,

2006 - A Very Good Year in MS Research  -  Dec 7, 2006
PR Newswire (press release),...a large phase III trial is now underway; -- oral cladribine (an immune-modulating drug by Serono), now being tested in an international Phase 3 clinical

European Commission Approves Revision of Therapeutic Indication ...  Jul 9, 2006
Additional therapy options are currently under development at Serono, including cladribine tablets, currently in Phase III studies and potentially the first ... -Yahoo! News



Phase III Trial Of Oral Cladribine, A Novel Investigational ...  May 5, 2006
Serono (drt-x: SEO and NYSE: SRA) announced today that recruitment in the US is beginning for the Phase III CLARITY study (CLAdRIbine Tablets in Treating MS ... - Medical News Today

Phase III Trial of Oral Cladribine, a Novel Investigational ...  May 4, 2006
May 4, 2006 /PRNewswire-FirstCall/ -- Serono announced today that recruitment in the US is beginning for the Phase III CLARITY study (CLAdRIbine Tablets in ... - PharmaLive.com

Serono's Oral Drug Enrollment Is Challenging  May 5, 2006
0606 GMT [Dow Jones] Serono's (SRA) enrollment for the last phase of clinical testing of its oral multiple sclerosis drug Cladribine could be challenging ... - newratings.com

Serono expands multiple sclerosis trial to US  May 5, 2006
Serono has begun enrolling patients in the US into a phase III trial of oral cladribine for the treatment of patients with relapsing forms of multiple sclerosis ... - Pharmaceutical Business Review

Serono Enrolling US Patients To Oral MS Drug Trial -2-  May 4, 2006
MS drug to the market. Oral cladribine is also known under its suggested brand name Mylinax. Current treatments typically belong ... - Therapeutics Daily (subscription)





Teva Ends Work on Oral Copaxone  Mar 21, 2006
The Ivax-Serono product, called Mylinax, is a pill version of injectable cladribine, which treats a form of leukemia. "Previous ... - TheStreet.com

Tysabri poised for return to market  Mar 31, 2006
...mitoxantrone hydrochloride) and Serono/Pfizer's Rebif (r-IFN-B1a) loom as Tysabri's main competitors, while Serono's Mylinax (cladribine) (expected to file for ... - Pharmaceutical Business Review

Biogen says Tysabri, new pill to keep it MS leader  Mar 10, 2006
...currently conducting Phase III tests on its FTY720 drug to be used as an oral treatment for MS, while Serono also has an oral version of its cladribine drug in ... - Reuters

Seronons 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
...of treatment. The Phase III CLARITY (CLAdRIbine Tablets Treating MS OrallY) study of oral cladribine is enrolling patients. In 2005 ... - MSN Money

Serono: On the Block and On the Clock  Feb 9, 2006
An oral drug for MS (cladribine) has a long and not-so-illustrious history, and I'm similarly not too optimistic on other drugs like zanolimumab (cancer) or ... - Motley Fool

Serono: On the Block and On the Clock  09 Feb 2006
An oral drug for MS (cladribine) has a long and not-so-illustrious history, and I'm similarly not too optimistic on other drugs like zanolimumab (cancer) or ... - Motley Fool

Serono's 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
...m - Progress in key MS clinical trials - REGARD 1st year of treatment completed in Rebif(R) vs Copaxone head-to-head study - CLARITY: oral cladribine Phase III ... - PR Newswire

Seronons 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
...of treatment. The Phase III CLARITY (CLAdRIbine Tablets Treating MS OrallY) study of oral cladribine is enrolling patients. In 2005 ... - MSN Money

Serono sales, profits miss forecasts, mum on M&A  Feb 5, 2006
Serono also said it had started enrolling patients to take part in a Phase III trial for its oral cladribine drug, one of the two frontrunners in the race to ... - Reuters

Serono sales, profits miss forecasts, mum on M&A  Feb 6, 2006
Serono also said it had started enrolling patients to take part in a Phase III trial for its oral MS drug cladribine and said it was confident it would beat ... - Reuters

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional